Skip to main content
. 2015 Oct 19;36(8):1374–1383. doi: 10.1177/0271678X15610786

Figure 3.

Figure 3.

miR-122 mimic given intravenously (i.v.) but not intracerebroventricularly (i.c.v.) decreases brain infarction after MCAO in rats. Scrambled miRNA mimic and miR-122 mimic were wrapped using PEG-liposomes prior to i.v. or i.c.v. administration after MCAO. (a) Cresyl Violet staining of coronal brain sections from five different rats. Column 1 sections are from a sham control. Column 2 sections are from scramble miRNA-MCAO rats. Column 3 sections are from miR-122 mimic MCAO (0.6mg/kg i.c.v.). Column 4 sections are from miR-122 mimic MCAO (0.6mg/kg i.v.). Column 5 sections are from miR-122 mimic MCAO (2.4mg/kg i.v.). (b) Following MCAO, miR-122 mimic (0.6 mg/kg i.v.) decreased infarction volume compared to scramble miRNA (*p < 0.05) and miR-122 (2.4 mg/kg i.v.) also decreased infarction volume compared to scramble miRNA (**p < 0.01). There was no significant difference of infarction volume for miR-122 mimic (0.6 mg/kg i.c.v) compared to scramble miRNA 24 hours following MCAO. Infarction volumes are on the Y-axis. *p < 0.05, **p < 0.01 for miR-122 mimic-MCAO vs. scramble miRNA-MCAO. n = 6/group.